Trial Profile
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary)
- Indications Sickle cell anaemia
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms Crescent
- Sponsors Eli Lilly and Company
- 15 Aug 2014 New trial record
- 12 Dec 2012
- 23 Jan 2012